Privately held Impel Neuropharma Inc. is looking to thrust its lead asset, INP-104, into the highly competitive migraine therapeutics mix as it embarks on the phase III trial of the drug-device candidate. A successful effort could enable an NDA filing by year-end using the 505(b)(2) pathway.